58.00 USD
↗ 3.85 (7.11%)AT CLOSE (11:59 AM EDT)
AnaptysBio, Inc. Common Stock
ANABNASDAQ • USD
58.38
↗ 0.38 (0.66%)
POST MARKET (AS OF 04:15 PM EDT)
Post Market
AS OF 04:15 PM EDT
58.38
↗ 0.38 (0.66%)
Market: CLOSED
AnaptysBio, Inc. Common Stock (ANAB) trades at $58.00 per share. Both sides of the analysis point lower: technicals flash "Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 1/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jul 17, 2026.
Open?$53.43
High?$58.62
Low?$53.17
Prev. Close?$54.15
Volume?732.6K
Avg. Volume?677.2K
VWAP?$57.50
Rel. Volume?1.08x
Bid / Ask
Bid?$57.20 × 200
Ask?$59.99 × 100
Spread?$2.79
Midpoint?$58.60
Valuation & Ratios
Market Cap?1.7B
Shares Out?29.6M
Float?17.3M
Float %?58.9%
P/E Ratio?N/A
P/B Ratio?134.72
EPS?-$0.90
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Employees
104
Market Cap
1.6B
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2017-01-26
Address
10770 WATERIDGE CIRCLE, SUITE 210
SAN DIEGO, CA 92121
Phone: 858-362-6295
SAN DIEGO, CA 92121
Phone: 858-362-6295
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?6
Z-Score?24
Momentum?50
Short Sent.?11
Piotroski F-Score?1/9Weak
Altman Z-Score?1.64Distress
Confidence?65%Moderate
Short InterestSqueeze Risk
Short % of Float?29.83%Squeeze Risk
Short Interest?5.1M
Days to Cover?8.3
Free Float17.3M
Avg Daily Volume622.5K
Settlement Date2026-06-30
Financial Health
Current Ratio?7.58Strong
Quick Ratio?7.58Strong
Cash Ratio?5.96Strong
Debt/Equity?0.00Low
ValuationRICHLY VALUEDvs 1 peers + S&P 500
Score33/100
P/E?N/A▾
P/B?134.72HIGH▾
Peers100
S&P3
P/S?7.39HIGH▾
Peers100
S&P16
P/FCF?389.5PRICEY▾
Peers100
S&P3
EV/EBITDA?35.5HIGH▾
Peers100
S&P8
EV/Sales?6.32HIGH▾
Peers100
S&P25
Returns & Efficiency
ROE?-210.1%WEAK▾
S&P3
ROA?-8.1%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$4.4M
Enterprise Value?$1.5B
Fundamentals ratios updated end of day